{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:42:56Z","timestamp":1788212576183,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03296-1","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T09:04:06Z","timestamp":1673341446000},"page":"570-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-0653","authenticated-orcid":false,"given":"Katerina","family":"Saltiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Simeakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Karapanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alevizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"6","key":"3296_CR1","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"M.E. Cabanillas, M. Ryder, C. Jimenez, Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 40(6), 1573\u20131604 (2019)","journal-title":"Endocr. Rev."},{"issue":"8","key":"3296_CR2","doi-asserted-by":"publisher","first-page":"T27","DOI":"10.1530\/ERC-20-0110","volume":"27","author":"R Dadu","year":"2020","unstructured":"R. Dadu, R. Bagheri-Yarmand, M.D. Ringel, E.G. Grubbs, M. Zafereo, G. Cote, R.F. Gagel, B.G. Robinson, K.R. Shaw, M.I. Hu, Hereditary endocrine tumours: Current state-of-the-art and research opportunities: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocr.-Relat. Cancer 27(8), T27\u2013T39 (2020)","journal-title":"Endocr.-Relat. Cancer"},{"issue":"3","key":"3296_CR3","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/EJE-22-0312","volume":"187","author":"K Saltiki","year":"2022","unstructured":"K. Saltiki, G. Simeakis, O. Karapanou, M. Alevizaki, Management of endocrine disease: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. Eur. J. Endocrinol. 187(3), R53\u2013r63 (2022)","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"3296_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr.","year":"2015","unstructured":"S.A. Wells Jr., S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid.: Off. J. Am. Thyroid. Assoc. 25(6), 567\u2013610 (2015)","journal-title":"Thyroid.: Off. J. Am. Thyroid. Assoc."},{"issue":"12","key":"3296_CR5","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1210\/jc.2014-2811","volume":"99","author":"ME Cabanillas","year":"2014","unstructured":"M.E. Cabanillas, M.I. Hu, C. Jimenez, Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat\u2013and with which drug\u2013those are the questions. J. Clin. Endocrinol. Metab. 99(12), 4390\u20134396 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3296_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","volume":"4","author":"J Hadoux","year":"2016","unstructured":"J. Hadoux, F. Pacini, R.M. Tuttle, M. Schlumberger, Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 4(1), 64\u201371 (2016)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"3296_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr.","year":"2012","unstructured":"S.A. Wells Jr., B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30(2), 134\u2013141 (2012)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"29","key":"3296_CR8","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"R. Elisei, M.J. Schlumberger, S.P. M\u00fcller, P. Sch\u00f6ffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31(29), 3639\u20133646 (2013)","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"3296_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"V. Subbiah, M.I. Hu, L.J. Wirth, M. Schuler, A.S. Mansfield, G. Curigliano, M.S. Brose, V.W. Zhu, S. Leboulleux, D.W. Bowles et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 9(8), 491\u2013501 (2021)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"3296_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N. Engl. J. Med. 383(9), 825\u2013835 (2020)","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"3296_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1530\/EJE-12-0388","volume":"167","author":"M Alevizaki","year":"2012","unstructured":"M. Alevizaki, K. Saltiki, G. Rentziou, A. Papathoma, L. Sarika, V. Vasileiou, E. Anastasiou, Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression. Eur. J. Endocrinol. 167(6), 799\u2013808 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"3296_CR12","doi-asserted-by":"crossref","unstructured":"P. Kazakou, G. Simeakis, M. Alevizaki, K. Saltiki. Medullary thyroid carcinoma (MTC): unusual metastatic sites. Endocrinol. Diabetes Metab. Case Rep. 2021 (2021)","DOI":"10.1530\/EDM-21-0063"},{"issue":"5","key":"3296_CR13","first-page":"791","volume":"24","author":"N Thomakos","year":"2010","unstructured":"N. Thomakos, A. Rodolakis, N. Akrivos, N. Skampardonis, M. Sotiropoulou, I. Biliatis, M. Alevizaki, A. Antsaklis, Metastatic medullary carcinoma of the vulva in a patient with MEN IIb syndrome. vivo (Athens, Greece) 24(5), 791\u2013794 (2010)","journal-title":"vivo (Athens, Greece)"},{"issue":"1","key":"3296_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000493977","volume":"8","author":"EM Opsahl","year":"2019","unstructured":"E.M. Opsahl, L.A. Akslen, E. Schlichting, T. Aas, K. Brauckhoff, A.I. Hagen, A.F. Rosenlund, E. Sigstad, K.K. Gr\u00f8holt, L. M\u00e6hle et al. Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway: a nationwide population-based study. Eur. Thyroid J. 8(1), 31\u201340 (2019)","journal-title":"Eur. Thyroid J."},{"key":"3296_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-017-0041-6","volume":"10","author":"G Geller","year":"2017","unstructured":"G. Geller, J. Laskin, W.Y. Cheung, C. Ho, A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res. 10, 6 (2017)","journal-title":"Thyroid Res."},{"key":"3296_CR16","doi-asserted-by":"publisher","first-page":"955629","DOI":"10.3389\/fonc.2022.955629","volume":"12","author":"R Zhang","year":"2022","unstructured":"R. Zhang, W. Zhang, C. Wu, Q. Jia, J. Chai, Z. Meng, W. Zheng, J. Tan, Bone metastases in newly diagnosed patients with thyroid cancer: A large population-based cohort study. Front. Oncol. 12, 955629 (2022)","journal-title":"Front. Oncol."},{"issue":"12","key":"3296_CR17","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1210\/jc.2016-2815","volume":"101","author":"JY Xu","year":"2016","unstructured":"J.Y. Xu, W.A. Murphy Jr., D.R. Milton, C. Jimenez, S.N. Rao, M.A. Habra, S.G. Waguespack, R. Dadu, R.F. Gagel, A.K. Ying et al. Bone metastases and skeletal-related events in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 101(12), 4871\u20134877 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3296_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/thy.2020.0206","volume":"31","author":"VF Koehler","year":"2021","unstructured":"V.F. Koehler, P. Adam, K. Frank-Raue, F. Raue, E. Berg, E. Hoster, S. Allelein, M. Schott, M. Kroiss, C. Spitzweg, Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer. Thyroid. Off. J. Am. Thyroid. Assoc. 31(3), 459\u2013469 (2021)","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"issue":"4","key":"3296_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/thy.2014.0361","volume":"25","author":"CN Chougnet","year":"2015","unstructured":"C.N. Chougnet, I. Borget, S. Leboulleux, C. de la Fouchardiere, F. Bonichon, L. Criniere, P. Niccoli, S. Bardet, O. Schneegans, S. Zanetta et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid. Off. J. Am. Thyroid. Assoc. 25(4), 386\u2013391 (2015)","journal-title":"Thyroid. Off. J. Am. Thyroid. Assoc."},{"issue":"6","key":"3296_CR20","doi-asserted-by":"publisher","first-page":"R241","DOI":"10.1530\/EJE-14-0726","volume":"172","author":"TP Links","year":"2015","unstructured":"T.P. Links, H.H. Verbeek, R.M. Hofstra, J.T. Plukker, Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies. Eur. J. Endocrinol. 172(6), R241\u2013R251 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3296_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-19-0259","volume":"27","author":"L Valerio","year":"2020","unstructured":"L. Valerio, V. Bottici, A. Matrone, P. Piaggi, D. Viola, V. Cappagli, L. Agate, E. Molinaro, R. Ciampi, A. Tacito et al. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. Endocr.-Relat. Cancer 27(2), 97\u2013110 (2020)","journal-title":"Endocr.-Relat. Cancer"},{"issue":"3","key":"3296_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3803\/EnM.2020.687","volume":"35","author":"M Kim","year":"2020","unstructured":"M. Kim, J.H. Yoon, J. Ahn, M.J. Jeon, H.K. Kim, D.J. Lim, H.C. Kang, I.J. Kim, Y.K. Shong, T.Y. Kim et al. Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience. Endocrinol. Metab. (Seoul., Korea) 35(3), 587\u2013594 (2020)","journal-title":"Endocrinol. Metab. (Seoul., Korea)"},{"issue":"2","key":"3296_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40801-021-00235-w","volume":"8","author":"T Mizuno","year":"2021","unstructured":"T. Mizuno, T. Sakai, K. Tanabe, T. Umemura, N. Goto, F. Ohtsu, Visualization of kinase inhibition-related adverse events using the japanese adverse drug event report database. Drugs Real World Outcomes 8(2), 197\u2013206 (2021)","journal-title":"Drugs Real World Outcomes"},{"issue":"4","key":"3296_CR24","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1530\/ERC-15-0555","volume":"23","author":"D Viola","year":"2016","unstructured":"D. Viola, L. Valerio, E. Molinaro, L. Agate, V. Bottici, A. Biagini, L. Lorusso, V. Cappagli, L. Pieruzzi, C. Giani et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr.-Relat. Cancer 23(4), R185\u2013R205 (2016)","journal-title":"Endocr.-Relat. Cancer"},{"issue":"2","key":"3296_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjsurg.2020.09.025","volume":"221","author":"ZT Sahli","year":"2021","unstructured":"Z.T. Sahli, J.K. Canner, M.A. Zeiger, A. Mathur, Association between age and disease specific mortality in medullary thyroid cancer. Am. J. Surg. 221(2), 478\u2013484 (2021)","journal-title":"Am. J. Surg."},{"issue":"6","key":"3296_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2265.2006.02659.x","volume":"65","author":"JW de Groot","year":"2006","unstructured":"J.W. de Groot, J.T. Plukker, B.H. Wolffenbuttel, T. Wiggers, W.J. Sluiter, T.P. Links, Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin. Endocrinol. 65(6), 729\u2013736 (2006)","journal-title":"Clin. Endocrinol."},{"key":"3296_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13010094","volume":"13","author":"A Matrone","year":"2020","unstructured":"A. Matrone, C. Gambale, A. Prete, P. Piaggi, V. Cappagli, V. Bottici, C. Romei, R. Ciampi, L. Torregrossa, L. De Napoli et al. Impact of advanced age on the clinical presentation and outcome of sporadic medullary thyroid carcinoma. Cancers 13, 1 (2020)","journal-title":"Cancers"},{"issue":"9","key":"3296_CR28","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"S. Roman, R. Lin, J.A. Sosa, Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9), 2134\u20132142 (2006)","journal-title":"Cancer"},{"issue":"1","key":"3296_CR29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hed.25463","volume":"41","author":"K Saltiki","year":"2019","unstructured":"K. Saltiki, G. Simeakis, E. Anagnostou, E. Zapanti, E. Anastasiou, M. Alevizaki, Different outcomes in sporadic versus familial medullary thyroid cancer. Head. Neck 41(1), 154\u2013161 (2019)","journal-title":"Head. Neck"},{"issue":"6","key":"3296_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00005792-198411000-00001","volume":"63","author":"MF Saad","year":"1984","unstructured":"M.F. Saad, N.G. Ordonez, R.K. Rashid, J.J. Guido, C.S. Hill Jr., R.C. Hickey, N.A. Samaan, Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63(6), 319\u2013342 (1984)","journal-title":"Medicine"},{"issue":"5","key":"3296_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/SLA.0b013e31813e66b9","volume":"246","author":"K Cupisti","year":"2007","unstructured":"K. Cupisti, A. Wolf, A. Raffel, M. Schott, D. Miersch, Q. Yang, C.F. Eisenberger, H.D. R\u00f6her, W.T. Knoefel, Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution\u2019s experience over 20 years. Ann. Surg. 246(5), 815\u2013821 (2007)","journal-title":"Ann. Surg."},{"issue":"5","key":"3296_CR32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s00268-018-4551-8","volume":"42","author":"S Jayakody","year":"2018","unstructured":"S. Jayakody, J. Reagh, M. Bullock, A. Aniss, R. Clifton-Bligh, D. Learoyd, B. Robinson, L. Delbridge, S. Sidhu, A.J. Gill et al. Medullary thyroid carcinoma: survival analysis and evaluation of mutation-specific immunohistochemistry in detection of sporadic disease. World J. Surg. 42(5), 1432\u20131439 (2018)","journal-title":"World J. Surg."},{"issue":"9","key":"3296_CR33","doi-asserted-by":"publisher","first-page":"e3582","DOI":"10.1210\/clinem\/dgab326","volume":"106","author":"F Raue","year":"2021","unstructured":"F. Raue, T. Bruckner, K. Frank-Raue, Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 106(9), e3582\u2013e3591 (2021)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"3296_CR34","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","volume":"40","author":"MA Duggan","year":"2016","unstructured":"M.A. Duggan, W.F. Anderson, S. Altekruse, L. Penberthy, M.E. Sherman, The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am. J. Surgical Pathol. 40(12), e94\u2013e102 (2016)","journal-title":"Am. J. Surgical Pathol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03296-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T10:11:52Z","timestamp":1701684712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["3296"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03296-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}